SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 Am ET

GlobeNewswire01/02 21:00

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire2024/12/10 21:30

SELLAS Reports Positive Survival Data From Mid-stage Trial of Its Leukemia Treatment

Seeking Alpha2024/12/09 22:28

SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient...

Benzinga2024/12/09 21:47

SELLAS Announces Positive Overall Survival and Overall Response Rate Data From the Phase 2 Trial of SLS009 in R/r AML

GlobeNewswire2024/12/09 21:45

SELLAS Announces Positive Data From Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

GlobeNewswire2024/11/27 21:45